Next Article in Journal
Disparity in Cancer Care: A Canadian Perspective
Previous Article in Journal
A Retrospective Chart Review Validates Indicator Results and Provides Insight into Reasons for Non-Concordance with Evidence-Based Guidelines
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 19
Issue 6
10.3747/co.19.1174
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Short Communication

Febrile Neutropenia Rates with Adjuvant Docetaxel and Cyclophosphamide Chemotherapy in Early Breast Cancer: Discrepancy between Published Reports and Community Practice—An Opdated Analysis

by
J. Younus
1,*,
T. Vandenberg
1,
M. Jawaid
2 and
M.A. Jawaid
3
1
Department of Medical Oncology, London Regional Cancer Program, London, ON, Canada
2
Schulich School of Medicine, Western University, London, ON, Canada
3
Department of Social Sciences, Western University, London, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2012, 19(6), 332-334; https://doi.org/10.3747/co.19.1174
Submission received: 6 September 2012 / Revised: 4 October 2012 / Accepted: 2 November 2012 / Published: 1 December 2012

Excerpt

Note: In lieu of an abstract, this is an excerpt from the first page.

Chemotherapy in the adjuvant setting for early breast cancer (EBC) has improved disease-free and overall survival, with benefits extended to elderly patients and to those with lymph-node-negative pathology. [...]
Keywords: febrile neutropenia; breast cancer; adjuvant chemotherapy febrile neutropenia; breast cancer; adjuvant chemotherapy

Share and Cite

MDPI and ACS Style

Younus, J.; Vandenberg, T.; Jawaid, M.; Jawaid, M.A. Febrile Neutropenia Rates with Adjuvant Docetaxel and Cyclophosphamide Chemotherapy in Early Breast Cancer: Discrepancy between Published Reports and Community Practice—An Opdated Analysis. Curr. Oncol. 2012, 19, 332-334. https://doi.org/10.3747/co.19.1174

AMA Style

Younus J, Vandenberg T, Jawaid M, Jawaid MA. Febrile Neutropenia Rates with Adjuvant Docetaxel and Cyclophosphamide Chemotherapy in Early Breast Cancer: Discrepancy between Published Reports and Community Practice—An Opdated Analysis. Current Oncology. 2012; 19(6):332-334. https://doi.org/10.3747/co.19.1174

Chicago/Turabian Style

Younus, J., T. Vandenberg, M. Jawaid, and M.A. Jawaid. 2012. "Febrile Neutropenia Rates with Adjuvant Docetaxel and Cyclophosphamide Chemotherapy in Early Breast Cancer: Discrepancy between Published Reports and Community Practice—An Opdated Analysis" Current Oncology 19, no. 6: 332-334. https://doi.org/10.3747/co.19.1174

APA Style

Younus, J., Vandenberg, T., Jawaid, M., & Jawaid, M. A. (2012). Febrile Neutropenia Rates with Adjuvant Docetaxel and Cyclophosphamide Chemotherapy in Early Breast Cancer: Discrepancy between Published Reports and Community Practice—An Opdated Analysis. Current Oncology, 19(6), 332-334. https://doi.org/10.3747/co.19.1174

Article Metrics

Back to TopTop